We are international
Donate
TEXT SIZE   


First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycin, Dexamethasone (PAD) vs VAD as induction treatment prior to High Dose Melphalan (HDM) in patients with multiple myeloma (MM)
By Pieter Sonneveld, M.D.
XIIth International Myeloma Workshop in Washington, DC
Pieter Sonneveld, M.D.
University Hospital
Rotterdam, Netherlands
02.23.09


To view the video full screen, click on the small button next to the volume control in the lower right hand corner.


 related articles